Microbiote et cancer bronchique: l'exemple de l'immunothérapie / Microbiota and lung cancer: an example of immunotherapy

L. Derosa (France)

Source: Virtual Congress 2021 – French programme 2021

Session: French programme 2021
Session type: Language session
Number: 63

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
L. Derosa (France). Microbiote et cancer bronchique: l'exemple de l'immunothérapie / Microbiota and lung cancer: an example of immunotherapy. Virtual Congress 2021 – French programme 2021

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Troubles respiratoires du sommeil et cancer : données épidémiologiques / Respiratory disorders associated with sleep and cancer: epidemiological data Source: Virtual Congress 2020 – French programme 2020: Part I Year: 2020
Mucoviscidose: enfin des traitements ciblés / Cystic fibrosis: targeted therapies, at last ! Source: Virtual Congress 2020 – French programme 2020: Part I Year: 2020
Prise en charge de l’emphysème : Approche personnalisée / Management of emphysema: personalised approach Source: Virtual Congress 2021 – French programme 2021 Year: 2021
Exploration de la fonction respiratoire selon l'âge / Lung function testing and age Source: Virtual Congress 2020 – French programme 2020: Part II Year: 2020
Où en sommes-nous dans le dépistage du cancer bronchique? Screening for lung cancer: where are we? Source: International Congress 2019 – French programme 2019: Part I Year: 2019
Risques cardiovasculaires et BPCO / Cardiovascular risks and COPD Source: Virtual Congress 2020 – French programme 2020: Part II Year: 2020
Exacerbation aiguë de la fibrose pulmonaire idiopathique: ce qu'il ne faut plus faire et ce qu'il reste à faire. / Acute exacerbation of idiopathic pulmonary fibrosis: what should not be done and what remains to be done? Source: Virtual Congress 2021 – French programme 2021 Year: 2021
Des lésions précancéreuses au cancer invasif / From precancerous lesions to invasive carcinoma Source: Virtual Congress 2020 – French programme 2020: Part I Year: 2020
Place des anti-IL5 dans les pathologies éosinophiliques (hors asthme sévère) / Anti-IL-5 therapy for indications other than severe asthma Source: Virtual Congress 2020 – French programme 2020: Part II Year: 2020
La thermoplastie dans l’asthme : corrélation clinique et histopathologiqueAsthma thermoplasty: clinical and histopathological correlation Source: International Congress 2017 – French Programme 2017 Year: 2017
Régulation de l'inflammation dans l'asthme : IL37 vs IL17Inflammatory regulation in asthma: IL37 vs IL17 Source: International Congress 2017 – French Programme 2017 Year: 2017
Syndrome obésité-hypoventilation: de la physiologie au traitementObesity hypoventilation: from pathophysiology to treatment Source: International Congress 2016 – ERS/French Programme I Year: 2016
La simvastatina no inhibe la inflamación producida por las células pulmonares Source: International Congress 2015 – Inflammation and remodelling in lung disease Year: 2015
Où en est-on dans la prise en charge de la Covid en septembre 2021 ? / Management of COVID-19: where are we ? Source: Virtual Congress 2021 – French programme 2021 Year: 2021
COPD: the Italian recommendationBPCO: le raccomandazioni Italiane Source: International Congress 2017 – ERS Italian Day programme Year: 2017
Le roi est mort, vive le roi? Source: Eur Respir J, 50 (1) 1701075; 10.1183/13993003.01075-2017 Year: 2017
Transplantation pulmonaire à l’heure de la médecine de précision Lung transplantation in the era of precision medicine Source: International Congress 2019 – French programme 2019: Part II Year: 2019
Médecine personnalisée et BPCO: où en sommes-nous ?Personalised medicine and COPD: where are we now? Source: International Congress 2016 – ERS/French Programme I Year: 2016